Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics (NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.
What happened According to a SEC filing dated May 14, 2026, Pivotal bioVenture Partners Investment Advisor increased its stake in Trevi Therapeutics (NASDAQ:TRVI) by 296,944 shares during the first quarter
The estimated transaction value was $3.32 million, calculated using the average unadjusted closing price for the quarter. At quarter end, the fund reported holding 1,553,726 shares, with a position value of $18.54 million. The net position value increased by $2.80 million, reflecting both share purchases and stock price appreciation.
What else to know – Pivotal bioVenture Partners’ buy brings its Trevi Therapeutics position to 6.63% of reportable AUM as of March 31, 2026 – Top holdings after the filing: – NASDAQ: PCVX: $79.75 million (28.5% of AUM) – NASDAQ: OCS: $44.68 million (15.97% of AUM) – NYSE: EVMN: $44.30 million (15.8% of AUM) – NASDAQ: ARQT: $31.94 million (11.4% of AUM) – NASDAQ: TRVI: $18.5 million (6.6% of AUM) – – As of May 13, 2026, Trevi Therapeutics shares were priced at $15.27, up 136.4% over the past year, outperforming the S&P 500 by 109.92 percentage points. Company Overview Company Snapshot – Trevi Therapeutics focuses on the development of Haduvio, an oral extended-release formulation of nalbuphine targeting serious neurologically mediated conditions such as chronic pruritus and chronic cough in idiopathic pulmonary fibrosis. – The company operates a clinical-stage biopharmaceutical model, generating value through pharmaceutical research and development with the aim of future commercialization and licensing agreements. – Primary customers include healthcare providers, specialists, and patients affected by chronic neurological and pulmonary conditions, with a focus on…